Pyopneumothorax during bevacizumab-containing chemotherapy in a patient with metastatic breast cancer

Int Cancer Conf J. 2015 May 1;5(1):40-44. doi: 10.1007/s13691-015-0222-x. eCollection 2016 Jan.

Abstract

Pyopneumothorax is a rare but troubling complication of bevacizumab. We herein report a case of pyopneumothorax in a patient with metastatic breast cancer during bevacizumab treatment. A 60-year-old female who was diagnosed with metastatic breast cancer (ER+ , PgR+ , HER2-, Ki67 <14 %, metastasized to lung, pleural, brain, subcutaneous tissue, and bone) was started on bevacizumab plus paclitaxel chemotherapy. Although the disease was well-controlled, pyopneumothorax was noted after 3 months of treatment and the chemotherapy was therefore stopped immediately. The pyopneumothorax was so intractable that no conservative treatment could successfully manage it. The patient underwent a radical operation using the technique of latissimus dorsi muscle transfer. The operation improved her general condition and lead to hormonal therapy. Our case indicates the successful management of a severe side effect of bevacizumab for a breast cancer patient.

Keywords: Bevacizumab; Breast cancer; Pyopneumothorax; Pyothorax.

Publication types

  • Case Reports